Posted 17 July, 2023

Sagimet Biosciences Inc. IPO completed

IPO completed detected for ticker Nasdaq:SGMT in a 424B4 filed on 17 July, 2023.

  This is an initial public offering of shares of Series A common stock of Sagimet Biosciences Inc.  

Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of Sagimet Biosciences Inc.
Health Care/Life Sciences • Biotechnology
Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.
Market Cap
View Company Details